Home / Private raises / Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc.
Pharmaceuticals · Durham, North Carolina · $57.5M sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | D (new) | $57.5M | $57.5M | 7 | 506(b) | Equity, Options/warrants, Security to be acquired | Oct 30 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Issuer
| Industry | Pharmaceuticals |
| Located | Durham, North Carolina |
| Entity | Corporation |
| Incorporated | Nevada |
| SEC CIK | 1919246 |
People named in the latest filing
| Name | Role |
|---|---|
| Scott Plesha | Chief Executive Officer |
| John M. Gay | Chief Financial Officer, Treasurer and Secretary |
| Sai Rangarao | Chief Commercial Officer |
| Richard Baxter | Director |
| Peter Greenleaf | Chairman |
| Ezra Friedberg | Director |
| Todd Davis | Director |
| Richard Malamut | Director |
| Matthew Pauls | Director |
| Andrew Einhorn | Director |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
